Literature DB >> 30855996

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Gianluigi Savarese1, Naveed Sattar2, James Januzzi3, Subodh Verma4, Lars H Lund1, David Fitchett5, Cordula Zeller6, Jyothis T George7, Martina Brueckmann7,8, Anne Pernille Ofstad9, Silvio E Inzucchi10, Christoph Wanner11, Bernard Zinman12, Javed Butler13.   

Abstract

Entities:  

Keywords:  heart failure; hospitalization; mortality

Mesh：

Substances：

Year:  2019        PMID： 30855996     DOI： 10.1161/CIRCULATIONAHA.118.038339

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

Review 2.  Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Diabetol Int       Date:  2020-06-11

Review 3.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

Review 4.  Predictors of heart failure development in type 2 diabetes: a practical approach.

Authors:  Subodh Verma; Abhinav Sharma; Naresh Kanumilli; Javed Butler
Journal:  Curr Opin Cardiol       Date:  2019-09       Impact factor: 2.161

Review 5.  Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.

Authors:  Sanjay Kalra; Kimi K Shetty; Vertivel B Nagarajan; Jignesh K Ved
Journal:  Diabetes Ther       Date:  2020-03-04       Impact factor: 2.945

Review 6.  Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.

Authors:  Gianluigi Savarese; Benedikt Schrage; Francesco Cosentino; Lars H Lund; Giuseppe M C Rosano; Petar Seferovic; Javed Butler
Journal:  ESC Heart Fail       Date:  2020-09-10

Review 7.  Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.

Authors:  Qingchun Zeng; Qing Zhou; Weitao Liu; Yutong Wang; Xingbo Xu; Dingli Xu
Journal:  Front Cardiovasc Med       Date:  2021-02-10

8.  Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value.

Authors:  Xingxing Li; Zongjing Fan; Jie Cui; Dong Li; Jinjin Lu; Xiaoyun Cui; Liandi Xie; Yang Wu; Qian Lin; Yan Li
Journal:  Front Cardiovasc Med       Date:  2022-02-16

9.  Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.

Authors:  Subodh Verma; Abhinav Sharma; Bernard Zinman; Anne Pernille Ofstad; David Fitchett; Martina Brueckmann; Christoph Wanner; Isabella Zwiener; Jyothis T George; Silvio E Inzucchi; Javed Butler; C David Mazer
Journal:  Diabetes Obes Metab       Date:  2020-03-29       Impact factor: 6.577

Review 10.  What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

Authors:  Muhammad Shahzeb Khan; Muthiah Vaduganathan
Journal:  Curr Diab Rep       Date:  2020-10-11       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.